Pfizer Inc. Stock
€21.99
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Pfizer
sharewise wants to provide you with the best news and tools for Pfizer, so we directly link to the best financial data sources.
Financials
News
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and
5 Healthcare Plays Powering the Sector’s Big Comeback
After years of underperformance, the healthcare sector may finally be waking up. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV), which tracks the largest U.S. healthcare companies, has
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of
TrumpRx Brings Pfizer Into the Green—Is It a Buy?
Pfizer (NYSE: PFE) is no stranger to income investors. The drugmaker, famous for treatments including Lipitor, Viagra, and Zoloft, has now increased its dividend payout for 16 consecutive years
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
After tanking in early August, the world’s most valuable pharmaceutical stock has roared back with a vengeance. That firm is Eli Lilly and Company (NYSE: LLY), the maker of the wildly popular
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However
Pfizer is Locking in New Growth Through a New Acquisition
In the United States' healthcare sector, a new growth theme is emerging that nearly all companies want to capitalize on. Like artificial intelligence for technology stocks, weight loss drug
3 Long-Term Dividend Buys You Can Get for Under $50
Despite ongoing concerns about overvalued stocks, many value investors sleep well at night. That’s because the key to long-term value investing is total return, which includes a healthy, growing
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
Today’s stock market focus is centered on one single sector: technology stocks.
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one
Top 5 Undervalued Dividend Stocks With Strong Payout Potential
In a market where mega-cap growth and tech stocks continue to dominate headlines and stretch valuations, income-oriented investors may feel sidelined. But for those with a long-term perspective
Down 50%, Should You Buy the Dip on Pfizer?
Pfizer (NYSE: PFE) is deeply unloved today. There are a couple of reasons for this that are important, but the big story revolves around the company's drug portfolio. With three drugs facing patent
Do These 3 Healthcare Stocks Need a Checkup?
The pharmaceutical industry is highly competitive, and currently, the leading company in the sector is likely Eli Lilly (NYSE: LLY). That's driven by the fact that Eli Lilly makes the weight loss
2 Headwinds Facing Pfizer Stock Going Into 2026
The past few years have been a challenging ride for Pfizer (NYSE: PFE). Since the company made history in 2022, when it became the first in the biopharma industry to reach $100 billion in annual
2 Top Dividend Stocks to Buy Now and Hold For a Decade
New investing trends pop up on Wall Street all the time. Over the past seven years, we have witnessed excitement surrounding cannabis stocks, the metaverse, artificial intelligence, and more
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever
Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) are two of the largest and most respected pharmaceutical companies in the world. If you are looking to buy high-quality companies, they should
This 7% Yielder Could Be a Top AI Play
Shares of the pharmaceutical giant Pfizer (NYSE: PFE) have suffered over the last three years, falling some 50% since December 2022. Shares have been weighed down by the collapse in revenue from its
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
While few investors have successfully timed the markets, buy-and-hold strategies tend to yield favorable results over the long term. The key is to select well-run companies that make highly
Did Pfizer Just Say "Checkmate" to Novo Nordisk?
The words "Ozempic" and "Wegovy" almost have become household names as these products have changed the lives of many – from our own friends and family to celebrities. These drugs, prescribed for
Is This the Best Value Stock to Buy While Markets Are Volatile?
You may have noticed that the markets are exceptionally volatile at the moment. That's true whether we're talking about stocks, cryptocurrencies, or commodities.
During turbulent times, many
This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
The past five years have been a roller-coaster ride for Pfizer (NYSE: PFE). The pharmaceutical giant shook up its business -- for instance, by getting rid of its off-patent drug unit -- and made a
Is Pfizer's 6.9%-Yielding Dividend Still Safe?
Healthcare giant Pfizer (NYSE: PFE) has been offering a high yield for some time. But that hasn't been enough to get investors to buy up the stock. You can see that in its sluggish share price, and
2 No-Brainer Healthcare Stocks to Buy Now
The obesity drug market is creating trillion-dollar winners, but you don't have to pay premium prices for exposure. Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) are both relatively
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade
2 Giant Healthcare Stocks to Buy Hand Over Fist in November
The healthcare sector is a highly competitive, highly regulated, and technically complex industry. Which is why most investors should probably stick to the industry's largest companies.
With a
Down 55%, Should You Buy the Dip on Pfizer?
The last five or six years have been a roller-coaster ride for Pfizer (NYSE: PFE) and its shareholders. It was a fun ride on the way up, but after peaking in late 2021, the pharmaceutical giant's